Quantinno Capital Management LP Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Quantinno Capital Management LP increased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 78.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,930 shares of the medical research company's stock after buying an additional 16,224 shares during the period. Quantinno Capital Management LP owned 0.07% of Charles River Laboratories International worth $6,817,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of CRL. D1 Capital Partners L.P. bought a new stake in Charles River Laboratories International in the 4th quarter worth about $172,752,000. Norges Bank bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $98,886,000. Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after acquiring an additional 335,658 shares in the last quarter. Nomura Holdings Inc. purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,820,000. Finally, Raymond James Financial Inc. bought a new stake in Charles River Laboratories International during the fourth quarter worth $42,776,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of recent analyst reports. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Barclays boosted their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Thursday, May 8th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $172.31.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $0.42 during mid-day trading on Thursday, hitting $135.40. 99,095 shares of the stock traded hands, compared to its average volume of 982,255. The business's 50-day moving average price is $133.64 and its 200 day moving average price is $164.14. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a market cap of $6.65 billion, a PE ratio of 902.91, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.27 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).